LEN vs TRDA · rev $34.19B vs P/E 12, rev $210.8M
LEN (LEN) versus Entrada Therapeutics Inc (TRDA) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
LEN currently screens at market cap $0. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Not investment advice. Open the LEN and TRDA stock pages for the full models.
Not investment advice.